Shivalik Rasayan Ltd

Ginnerup Capital ApS has acquired 399,990 fully convertible warrants in Shivalik Rasayan Limited, representing 5.34% of the diluted paid-up share capital. This acquisition, made through a preferential allotment on September 14, 2026, increases Ginnerup Capital's total holding to 906,540 shares, or 12.16% of the diluted share capital. The warrants are convertible into equity shares at a ratio of 1:1. This disclosure is made pursuant to Regulation 29(1) of SEBI SAST Regulations, 2011.

Shivalik Rasayan Ltd has announced the closure of its trading window for directors, designated employees, and other insiders. This closure will be effective from October 01, 2026, until the declaration of the un-audited financial results for the quarter ending September 2026, and will remain closed for two days thereafter. The company will announce the date of the Board Meeting for approving these results in due course.

Shivalik Rasayan Limited's Board of Directors has approved the allotment of 2,82,000 equity shares and 9,47,990 fully convertible warrants. The equity shares were issued at Rs. 250 each, raising Rs. 7.05 crore, primarily to the 'Public' category. Additionally, 9,47,990 warrants were allotted at Rs. 250 each, raising Rs. 23.70 crore, to 'Promoter & Promoter Group' and 'Public' categories. This preferential allotment increases the company's paid-up equity share capital and will impact its fully diluted equity share capital upon warrant conversion.

Shivalik Rasayan Ltd has announced its 48th Annual General Meeting (AGM) will be held on September 28, 2026. The company will consider a final dividend of ₹0.50 per equity share. The Register of Members and Share Transfer books will be closed from September 22 to September 28, 2026, for the AGM and dividend payment. The dividend, if declared, will be paid by October 15, 2026, to shareholders of record as of September 21, 2026. Remote e-voting will be available from September 25 to September 27, 2026. The Annual Report for FY 2025-26 is also enclosed.

Shivalik Rasayan Limited has announced its 48th Annual General Meeting (AGM) scheduled for September 28, 2026. The company will also close its Register of Members and Share Transfer books from September 22 to September 28, 2026, for dividend payment and the AGM. A final dividend of Re 0.50 per Equity Share (10%) is recommended, subject to declaration at the AGM, with payment expected by October 15, 2026. Shareholders can participate via remote e-voting from September 25 to September 27, 2026. The Annual Report for FY 2025-26 is also enclosed.

Shivalik Rasayan Limited has filed a disclosure regarding the sale of 25,000 equity shares by Mr. Sanjay Bansal, a former Director and connected person. The transaction, valued at ₹68,31,455, occurred on the open market on August 21, 2026. This disclosure is made in compliance with Regulation 7(3) of the SEBI (Prohibition of Insider Trading) Regulations, 2015. Mr. Bansal's shareholding post-transaction is reduced to 0.16% of the company's equity.

Shivalik Rasayan Ltd has announced the record date for its 47th Annual General Meeting (AGM) and the final dividend for the financial year ended March 31, 2026. The AGM is scheduled for September 28, 2026. The record date for determining eligibility for dividend payment is set as September 21, 2026. Dividends, if approved at the AGM, will be paid from October 15, 2026, to shareholders in both electronic and physical forms.

Shivalik Rasayan's consolidated Q1 FY27 (quarter ended June 30, 2026) revenue was ₹96.34 Cr, up 7.9% YoY from ₹89.31 Cr but down 6.3% QoQ from ₹102.82 Cr — the sequential dip reflects agrochemical seasonality (Q4 is the stronger pre-kharif dispatch quarter) rather than demand weakness. Consolidated PAT (including minority interest) was ₹4.50 Cr, up 59.6% YoY though down 37.3% QoQ off the seasonally strong Q4 base. Standalone (agrochemicals + API only) revenue was ₹48.44 Cr (+4.7% YoY) and standalone PAT ₹2.66 Cr (+117.5% YoY) — the standalone and consolidated growth stories diverge because the consolidated book folds in the Pharma Formulation business via associate Medicamen Biotech Limited, whose segment revenue grew 11.3% YoY to ₹47.90 Cr. The headline PAT/EPS growth significantly outpaces core operating performance. Consolidated EBITDA (PBT before exceptional items + finance cost + depreciation − other income) was ₹11.18 Cr, up just 1.8% YoY from ₹10.98 Cr, and EBITDA margin slipped to 11.61% of operating revenue from 12.30% a year ago and 12.09% last quarter — a genuine, if modest, operating-margin compression. The 36.5% YoY jump in PBT (₹5.66 Cr vs ₹4.15 Cr) and the larger PAT/EPS gains were driven below the operating line: finance cost fell 20.6% YoY to ₹2.08 Cr and depreciation fell 8.4% YoY to ₹4.41 Cr, while reported EPS of ₹2.16 (vs ₹1.02 a year ago, +112% YoY) was boosted further by the shift in the minority-interest split — non-controlling interest absorbed only 24% of total consolidated PAT this quarter (₹1.10 Cr of ₹4.50 Cr) versus 43% a year ago (₹1.22 Cr of ₹2.82 Cr). On the standalone book, the API segment loss narrowed to ₹1.98 Cr from ₹2.96 Cr YoY, aiding overall PBT, while the Agrochemicals segment result was roughly flat YoY at ₹6.31 Cr. There is no formal management guidance on record for this quarter, and no analyst/street consensus estimate could be found for this print — Shivalik Rasayan carries limited institutional coverage, so vsStreet is marked unknown rather than assumed. No management press release accompanied the filing beyond the standard board-outcome letter, so there is no fresh commentary to reconcile against the numbers. Results are un-audited, subject only to a limited review by the statutory auditor (Rahul Chaudhary & Associates). Alongside the results, the board approved the FY26 annual report and set a September 28, 2026 AGM with a final dividend of ₹0.50/share (10%); separately, the company called an EGM (July 27, 2026) to approve raising ₹33 Cr via 3.72 lakh equity shares and 9.48 lakh warrants (announced July 24, 2026) — a capital raise that will add dilution once the warrants convert, alongside two rounds of open-market selling by a former director (50,000 and 60,000 shares in late July/early August). Going into Q2 FY27, revenue growth is intact but unspectacular (high-single-digit YoY), and the real swing factor behind reported profit has been financing/depreciation costs and the minority-interest mix rather than core margins, which are still drifting lower. That combination — solid EPS optics on a softening EBITDA margin — is worth tracking as the new equity/warrant issuance works through the share count over coming quarters.

Shivalik Rasayan Ltd has announced that its Board of Directors will convene on August 14, 2026, to consider and approve the un-audited financial results for the quarter ended June 30, 2026. The meeting will also review the draft Annual Report for the financial year 2025-26. Concurrently, the trading window for company securities, which closed on July 01, 2026, will reopen 48 hours after the financial results are declared.

Shivalik Rasayan Limited has filed an intimation regarding the sale of 50,000 equity shares by Mr. Sanjay Bansal, a former Director and Connected Person. The transaction occurred in the open market. This disclosure is made pursuant to Regulation 7(3) read with Regulation 6(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015, confirming compliance with the insider trading norms. The company requests this intimation be taken on record.